6-氯-1H-吡咯并[3,2-b]吡啶-2-羧酸甲酯 | 1083196-33-1

• 物质功能分类: 医药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 中文名称: 6-氯-1H-吡咯并[3,2-b]吡啶-2-羧酸甲酯
• 英文名称: methyl 6-chloro-1H-pyrrolo[3,2-b]pyridine-2-carboxylate
• CAS: 1083196-33-1
• 化学式: C₉H₇ClN₂O₂
• 分子量: 210.62
• InChiKey: KJDJURGGHBNVMM-UHFFFAOYSA-N

物化性质

• 沸点：
  362.9±37.0 °C(Predicted)
• 密度：
  1.453±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  55
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H312,H315,H319,H332,H335

反应信息

• 作为反应物：
  描述：

  6-氯-1H-吡咯并[3,2-b]吡啶-2-羧酸甲酯 、 4-叔丁基苄溴 在 sodium hydride 、 potassium hydroxide 作用下， 以 乙醇 为溶剂， 生成 1-[(4-Tert-butylphenyl)methyl]-6-chloropyrrolo[3,2-b]pyridine-2-carboxylic acid
  参考文献：
  名称：

  Discovery of indole inhibitors of chemokine receptor 9 (CCR9)

  摘要：

  Irritable bowel diseases (IBD) such as Crohn's disease (CD) and ulcerative colitis (UC) are serious chronic diseases affecting millions of patients worldwide. Studies of human chemokine biology has suggested C-C chemokine receptor 9 (CCR9) may be a key mediator of pro-inflammatory signaling. Discovery of agents that inhibit CCR9 may lead to new therapies for CD and UC patients. Herein we describe the evolution of a high content screening hit (1) into potent inhibitors of CCR9, such as azaindole 12. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2016.05.043
• 作为产物：
  描述：

  2,5-二氯吡啶-3-胺 在 氯化亚砜 、 palladium diacetate 、 三乙胺 作用下， 生成 6-氯-1H-吡咯并[3,2-b]吡啶-2-羧酸甲酯
  参考文献：
  名称：

  INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF

  摘要：

  本发明提供了作为血浆激肽酶抑制剂并具有相同理想特性的化合物和组合物。

  公开号：

  US20190284182A1

文献信息

• Inhibitors of plasma kallikrein and uses thereof
  申请人：Shire Human Genetic Therapies, Inc.

  公开号：US10730874B2

  公开（公告）日：2020-08-04

  The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

  本发明提供了可用作血浆钙激酶抑制剂并表现出理想特性的化合物及其组合物。
• SUBSTITUTED IMIDAZOPYRIDINES AS INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF
  申请人：Shire Human Genetic Therapies, Inc.

  公开号：EP3765459A1

  公开（公告）日：2021-01-20
• [EN] SUBSTITUTED IMIDAZOPYRIDINES AS INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF<br/>[FR] IMIDAZOPYRIDINES SUBSTITUÉES EN TANT QU'INHIBITEURS DE LA KALLICRÉINE PLASMATIQUE ET LEURS UTILISATIONS
  申请人：SHIRE HUMAN GENETIC THERAPIES

  公开号：WO2019178129A1

  公开（公告）日：2019-09-19

  The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
• INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF
  申请人：Shire Human Genetic Therapies, Inc.

  公开号：US20190284182A1

  公开（公告）日：2019-09-19

  The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

  本发明提供了作为血浆激肽酶抑制剂并具有相同理想特性的化合物和组合物。
• Discovery of indole inhibitors of chemokine receptor 9 (CCR9)
  作者：Bhaumik A. Pandya、Christian Baber、Audrey Chan、Brian Chamberlain、Haoqun Chandonnet、Jennifer Goss、Timothy Hopper、Blaise Lippa、Katherine Poutsiaka、Jan Romero、Sabrina Stucka、Mustafa Varoglu、Jing Zhang、Xin Zhang

  DOI：10.1016/j.bmcl.2016.05.043

  日期：2016.7

  Irritable bowel diseases (IBD) such as Crohn's disease (CD) and ulcerative colitis (UC) are serious chronic diseases affecting millions of patients worldwide. Studies of human chemokine biology has suggested C-C chemokine receptor 9 (CCR9) may be a key mediator of pro-inflammatory signaling. Discovery of agents that inhibit CCR9 may lead to new therapies for CD and UC patients. Herein we describe the evolution of a high content screening hit (1) into potent inhibitors of CCR9, such as azaindole 12. (C) 2016 Elsevier Ltd. All rights reserved.